Latest Articles

Publication Date
All News Scientific
Mechanisms and applications of mesenchymal stem cell exosomes in enhancing fertility - Stem Cell Research & Therapy

Mechanisms and applications of mesenchymal stem cell exosomes in enhancing fertility Stem Cell Research & Therapy

Published: Oct. 28, 2025, 2:15 p.m.
Read Full Article
Michelle Wise, MD, discusses levonorgestrel IUD offering effective endometrial protection during hormone therapy - Contemporary OB/GYN

Michelle Wise, MD, discusses levonorgestrel IUD offering effective endometrial protection during hormone therapy Contemporary OB/GYN

Published: Oct. 23, 2025, 8:33 p.m.
Read Full Article
WES-Aneuploidy Scores May Be Prognostic for Immunotherapy in dMMR Endometrial Cancer - OncLive

WES-Aneuploidy Scores May Be Prognostic for Immunotherapy in dMMR Endometrial Cancer OncLive

Published: Oct. 23, 2025, 6:03 p.m.
Read Full Article
Dana-Farber Research Uncovers Potential Targeted Therapy for Endometrial Cancer - Dana-Farber Cancer Institute

Dana-Farber Research Uncovers Potential Targeted Therapy for Endometrial Cancer Dana-Farber Cancer Institute

Published: Oct. 21, 2025, 9 a.m.
Read Full Article
Female Reproductive Digital Therapy Market Is Projected To Reach a Valuation of USD 12 Billion by 2035, Growing at a CAGR of 19.4% - industrytoday.co.uk

Female Reproductive Digital Therapy Market Is Projected To Reach a Valuation of USD 12 Billion by 2035, Growing at a CAGR of 19.4% industrytoday.co.uk

Published: Oct. 20, 2025, 10:14 a.m.
Read Full Article
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - The AI Journal

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen The AI Journal

Published: Oct. 18, 2025, 10:28 a.m.
Read Full Article
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - Business Wire

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen Business Wire

Published: Oct. 18, 2025, 10 a.m.
Read Full Article
Long-Term Benefit of Adjuvant Therapy for Endometrial Cancer Patients - Labroots

Long-Term Benefit of Adjuvant Therapy for Endometrial Cancer Patients Labroots

Published: Oct. 16, 2025, 10 a.m.
Read Full Article
Adjuvant Chemoradiotherapy Yields 10-Year OS and RFS Advantages in High-Risk Endometrial Cancer - OncLive

Adjuvant Chemoradiotherapy Yields 10-Year OS and RFS Advantages in High-Risk Endometrial Cancer OncLive

Published: Oct. 15, 2025, 5:46 p.m.
Read Full Article
Rucaparib Maintenance Therapy Displays Activity in Pretreated Recurrent/Metastatic Endometrial Cancer - OncLive

Rucaparib Maintenance Therapy Displays Activity in Pretreated Recurrent/Metastatic Endometrial Cancer OncLive

Published: Oct. 15, 2025, 12:10 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!